STANFORD, CA – April 24, 2024 – A protein primarily known for its role in stimulating red blood cell production, erythropoietin (EPO), has been found to play a critical and previously unrecognized role in dampening the immune system’s response to cancer. Identified nearly 40 years ago for its hematopoietic properties, new research reveals EPO as a potent immunosuppressor within the tumor microenvironment, capable of turning immune-resistant, "cold" tumors into "hot" battlegrounds teeming with cancer-fighting immune cells.
The groundbreaking study, led by researchers at Stanford University and published online today in Science, demonstrates that blocking EPO’s activity can dramatically alter the landscape of liver tumors in mice. When combined with existing immunotherapies, this approach led to the complete regression of established liver tumors in the majority of treated animals, which subsequently lived for the duration of the experiment. In stark contrast, control animals succumbed to their disease within a matter of weeks.
“This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer,” declared Edgar Engleman, MD, PhD, a distinguished professor of pathology and medicine at Stanford and senior author of the research. His enthusiasm for the discovery is palpable. “I could not be more excited about this finding, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials.” The lead author of the study is basic life research scientist David Kung-Chun Chiu, PhD.
This revelation recontextualizes decades of observations regarding EPO’s mysterious connection to cancer, offering a new avenue for therapeutic intervention that could potentially transform outcomes for patients with currently intractable cancers.
From Red Blood Cells to Immune Suppression
For decades, erythropoietin has been celebrated for its vital role in hematopoiesis, the process of red blood cell formation. Produced primarily by the kidneys, EPO acts on progenitor cells in the bone marrow, stimulating their differentiation into mature erythrocytes, which are essential for oxygen transport throughout the body. This well-established function led to the development of recombinant human EPO as a therapeutic agent for anemia, particularly in patients with chronic kidney disease or those undergoing chemotherapy.
However, the scientific community has long grappled with a perplexing dual nature of EPO, particularly in the context of malignancy. While beneficial for anemia, clinical observations hinted at a darker side: the administration of exogenous EPO in cancer patients sometimes appeared to accelerate tumor growth. This troubling correlation prompted significant concern and, eventually, regulatory action. The new research now provides a crucial immunological framework to understand this long-standing enigma, revealing EPO not just as a growth factor for red blood cells, but as a sophisticated modulator of the anti-tumor immune response.
A Breakthrough in Turning ‘Cold’ Tumors ‘Hot’
The terms "cold" and "hot" tumors have become central to the lexicon of modern oncology, particularly in the era of immunotherapy. "Hot" tumors are characterized by a significant infiltration of immune cells, notably T cells, which are primed to recognize and destroy cancer cells. These tumors often respond well to immune checkpoint inhibitors like anti-PD-1 therapies, which unleash the T cells to attack the cancer. Conversely, "cold" tumors are largely devoid of immune cells, creating an immune-privileged microenvironment where cancer can proliferate unchecked. These tumors are notoriously resistant to current immunotherapeutic approaches, representing a major clinical challenge.
The Stanford team’s discovery directly addresses this challenge. By demonstrating that blocking EPO activity can convert "cold" liver tumors into "hot" ones, they have identified a potential strategy to sensitize a broad range of cancers to existing and future immunotherapies. This transformation is not merely theoretical; the preclinical data shows a profound shift in the tumor microenvironment, moving from an immune-deserted landscape to one teeming with active, cancer-fighting immune cells. The subsequent combination with anti-PD-1 therapy, which further boosts the activity of these newly recruited immune cells, proved to be a powerful synergistic approach, leading to complete and durable tumor eradication in the experimental models.
A Historical Perspective: EPO’s Enigmatic Link to Cancer
The journey to understanding EPO’s role in cancer immunity is a testament to persistent scientific inquiry, bridging decades of fragmented observations with a unifying immunological explanation.
Early Discoveries and the Red Blood Cell Connection
Erythropoietin’s existence was first hypothesized in the early 20th century, with its identity as a glycoprotein hormone confirmed in the 1970s and its gene cloned in the 1980s. Its primary function – regulating erythropoiesis – was firmly established, leading to its widespread clinical application. Recombinant EPO became a blockbuster drug, revolutionizing the management of anemia in various chronic conditions. The medical community largely viewed EPO through the lens of its hematopoietic prowess, a powerful tool to combat low red blood cell counts.
The Troubling Link: Accelerated Tumor Growth and the FDA Warning
However, as EPO use expanded, a concerning pattern emerged in cancer patients. While effective at alleviating chemotherapy-induced anemia, several studies from more than a decade ago indicated that giving EPO to cancer patients might inadvertently accelerate tumor growth and worsen patient outcomes. This was a profound dilemma: a drug that improved quality of life by reducing anemia potentially jeopardized the very fight against cancer.
The connection was sufficiently striking and concerning that in 2007, the U.S. Food and Drug Administration (FDA) mandated a "black box warning" label on EPO-stimulating agents, cautioning against their use in people with cancers, especially those not undergoing myelosuppressive chemotherapy. This warning reflected the significant uncertainty and potential risk associated with EPO in oncology, even as the precise mechanism of its detrimental effect remained elusive.
Researchers also observed a clear correlation between the natural levels of EPO and its receptor (EPOR) in tumors and patient prognosis. "Those old reports showed clearly that the more EPO or EPOR there was in tumors, the worse off the patients were," Engleman recounted. Yet, despite these strong epidemiological and clinical signals, the direct link between EPO and cancer immunity remained unmade. The prevailing dogma of EPO as solely a red blood cell growth factor proved a significant conceptual barrier.
The Missing Piece: Unraveling EPO’s Immunosuppressive Function
"But the connection between EPO and cancer immunity was never made until now," Engleman emphasized. "In fact, it took a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer, because EPO is so well established as a red blood cell growth factor." This statement underscores the paradigm shift represented by the current findings. The Stanford team meticulously peeled back layers of cellular interactions to reveal EPO’s hidden agenda within the tumor microenvironment. Their work not only explains the historical observations but also opens a new therapeutic frontier.
Unveiling the Mechanism: How EPO Dampens Anti-Cancer Responses
The journey to uncover EPO’s immunosuppressive role required sophisticated experimental models and a deep dive into the complex cellular crosstalk within tumors.
Precision Mouse Models Pave the Way
The study’s success relied heavily on the innovative work of lead author Dr. David Kung-Chun Chiu, who developed and utilized advanced genome editing techniques to create several highly specific mouse models of liver cancer. These models were meticulously engineered to recapitulate specific genetic mutations, histological features, and responses to approved therapies observed in various subtypes of human liver cancers. Tumor formation was initiated either by injecting a combination of DNA encoding liver cancer-associated proteins into the animals’ tail veins or by implanting liver cancer cells directly into the animals’ livers. This rigorous approach ensured that the preclinical findings would have the highest possible translational relevance to human disease.
The ‘Cold’ vs. ‘Hot’ Tumor Dichotomy
A primary focus of the research was to understand the differential responses of tumors to common immunotherapies, specifically those targeting the PD-1 molecule on immune T cells. Anti-PD-1 therapies, such as Keytruda, work by blocking the ability of cancer cells to "turn off" T cells, thereby unleashing the immune system to attack the tumor. While these therapies have transformed outcomes for some cancers (e.g., melanoma, Hodgkin’s lymphoma, certain lung cancers), a large majority of tumors, including most liver, pancreas, colon, breast, and prostate cancers, remain stubbornly resistant.
Consistent with observations in human liver cancers, the researchers found that certain combinations of genetic mutations in their mouse models led to the development of "cold" tumors. These tumors were largely ignored by the immune system, exhibiting minimal T-cell infiltration and consequently showing no shrinkage when treated with anti-PD-1 therapy. In contrast, other genetic configurations resulted in "hot" or "inflamed" tumors, characterized by a robust presence of T cells. These "hot" tumors were highly sensitive to anti-PD-1 treatment, which effectively triggered the T cells to launch a potent anti-cancer assault.
Hypoxia: The Root Cause of Elevated EPO
The pivotal moment in the investigation came with an unexpected observation: the "cold" tumors displayed significantly elevated levels of EPO compared to their "hot" counterparts. This increase, the researchers theorized, was likely triggered by the oxygen-poor microenvironment—a condition known as hypoxia—prevalent within these immune-resistant tumors. Hypoxia is a common feature of rapidly growing tumors, as their demand for oxygen often outstrips the blood supply. In response, cancer cells and surrounding stromal cells produce proteins that, in turn, ramp up the production of EPO. The conventional understanding was that this EPO production was a compensatory mechanism, aimed at increasing red blood cell formation to combat the low oxygen levels within the tumor.
"Hypoxia in tumors has been studied for decades," Engleman noted. "It just didn’t dawn on anyone, including me, that EPO could be doing anything in this context other than serving as a red blood cell growth factor." This statement highlights the entrenched scientific dogma that the Stanford team successfully challenged.
Macrophages: The Immune System’s Double Agents
Curiosity piqued, the researchers delved deeper. They cross-referenced their findings with existing databases, confirming that elevated EPO levels are indeed correlated with poorer survival in human patients across a spectrum of cancers, including those of the liver, kidney, breast, colon, and skin. This strong human correlation provided further impetus for their mechanistic investigation.
The team then began to "tinker" with the tumor cells’ ability to produce EPO. The results were astounding: mutations that had previously led to the development of "cold" tumors now caused "hot" tumors when the tumor cells were modified to be unable to make EPO. Conversely, "hot" tumors that had previously been successfully eradicated by the immune system thrived when they were engineered to produce elevated levels of EPO. This direct causal link between tumor-derived EPO and immune suppression was undeniable.
Further exhaustive research revealed the precise cellular mechanism: in "cold" tumors, the tumor cells actively produce and secrete EPO. This secreted EPO then binds to specific receptors (EPOR) located on the surface of immune cells called macrophages. Upon binding, these macrophages undergo a critical functional switch, transforming into an immunosuppressive phenotype. In this altered state, they actively "shoo away" cancer-killing T cells from the tumor site and dampen any residual T-cell activity, effectively creating an immune exclusion zone. This EPO-moderated crosstalk between tumor cells and macrophages was identified as the crucial pathway by which EPO orchestrates immune evasion.
The EPO-Macrophage Axis: A New Target
The clinical significance of this newly identified EPO-macrophage axis became profoundly clear when the researchers studied the combinatorial effect of simultaneously blocking the EPO signaling pathway and the anti-PD-1 pathway. In these crucial experiments, mice with "cold" liver tumors treated with control agents or anti-PD-1 therapy alone showed no survival beyond eight weeks after tumor induction. However, a significant improvement was observed in mice whose macrophages were genetically unable to express the EPO receptor: 40% of these animals lived for 18 weeks, the duration of the experiment.
The most dramatic results came when anti-PD-1 treatment was administered to mice lacking the EPO receptor on their macrophages. In this combined therapy group, all animals lived for the entire duration of the experiment, demonstrating complete and durable tumor regression. "It’s simple," Engleman concluded. "If you remove this EPO signaling, either by lowering the hormone levels or by blocking the receptors on the macrophages, you don’t just get a reduction in tumor growth, you get tumor regression along with sensitivity to anti-PD-1 treatment." This powerful synergy underscores the potential of targeting the EPO pathway to unlock the full potential of existing immunotherapies.
Compelling Evidence: Data Supporting the Discovery
The scientific rigor of the study is underpinned by a robust body of preclinical and correlative human data, painting a consistent picture of EPO’s critical role in cancer immunity.
Dramatic Regression in Preclinical Models
The mouse model experiments provided the most direct and compelling evidence. The ability to genetically manipulate EPO production and receptor expression within the tumor microenvironment allowed the researchers to definitively establish causality.
- Conversion of ‘Cold’ to ‘Hot’ Tumors: When tumor cells that typically produce "cold" tumors were modified to be unable to synthesize EPO, they transformed into "hot" tumors, characterized by significant immune cell infiltration. This was a direct functional demonstration of EPO’s role in maintaining an immune-excluded state.
- Reversal of Immunosuppression: Conversely, engineering "hot" tumors to produce elevated levels of EPO led to their evasion of the immune system, allowing them to thrive even in the presence of immune cells that would normally clear them.
- Synergistic Efficacy: The most impactful data came from the combination therapy experiments. While anti-PD-1 alone had no effect on "cold" tumors, its combination with interventions that disrupted EPO signaling—either by eliminating EPO production or by blocking its receptor on macrophages—resulted in:
- Complete Tumor Regression: Most mice experienced complete disappearance of existing liver tumors.
- Extended Survival: Treated animals lived for the entire experimental duration, while controls survived only a few weeks.
- Macrophage-Specific Impact: Mice with macrophages genetically lacking the EPO receptor demonstrated significantly improved survival (40% at 18 weeks), which was further boosted to 100% survival when combined with anti-PD-1 therapy. This pinpointed macrophages as the key immune cell type mediating EPO’s immunosuppressive effects.
Human Data Corroborates Mouse Findings
Beyond the direct experimental manipulation in mice, the study drew strength from historical and correlative human data:
- Historical Tumor Acceleration: The well-documented phenomenon of accelerated tumor growth in anemic cancer patients receiving exogenous EPO, which led to the 2007 FDA black box warning, now has a plausible immunological explanation.
- Prognostic Correlation: Analysis of existing patient databases consistently showed that elevated levels of naturally occurring EPO and its receptor (EPOR) in tumors correlated with poorer patient prognosis across various cancer types, including liver, kidney, breast, colon, and skin cancers. This indicates that the mechanism observed in mice is likely conserved and clinically relevant in humans.
- Hypoxia as a Driver: The observation that "cold" tumors often exhibit hypoxia, and that hypoxia induces EPO production, provides a clear upstream driver for EPO’s immunosuppressive activity in human cancers as well. This mechanistic link strengthens the translational potential of the discovery.
The Power of Combination Therapy
The findings strongly advocate for combination therapies. While targeting EPO signaling alone showed a significant benefit, its combination with anti-PD-1 immunotherapy yielded the most profound results. This suggests that blocking EPO acts as a "priming" step, converting "cold" tumors into "hot" ones, thereby making them susceptible to the T-cell activation provided by checkpoint inhibitors. This synergistic effect offers a powerful strategy to overcome immunotherapy resistance, a major hurdle in current oncology.
Official Acclaim and Future Directions
The discovery has been met with significant scientific excitement, signaling a new frontier in cancer research and therapy development.
Expert Voices: Excitement for Clinical Translation
Dr. Engleman’s emphatic statements encapsulate the sentiment within the scientific community. His description of the finding as a "fundamental breakthrough" underscores its potential to reshape our understanding of cancer immunology. The hope for rapid translation to human trials reflects the urgency and clinical need for new effective cancer therapies, particularly for those cancers currently resistant to immunotherapy. The recontextualization of EPO’s historical enigma is also a source of satisfaction for researchers who have long pondered its paradoxical effects.
"I continue to be amazed by this finding," Engleman reiterated, acknowledging the depth and unexpected nature of the discovery. His optimism is not unfounded; the clear mechanistic pathway elucidated by the study provides a solid foundation for drug development.
Navigating the Path to Human Trials
The immediate next step, as articulated by Dr. Engleman, is to design and move treatments targeting EPO signaling towards human clinical trials. This transition from preclinical models to human patients is a complex process, but the strong mechanistic understanding and compelling mouse data provide a robust rationale.
One critical consideration will be the potential side effects of targeting EPO. Non-specifically blocking the EPO protein could lead to anemia, given its essential role in red blood cell production. However, Engleman speculates that this might be an "acceptable trade-off" for an effective cancer therapy, especially for patients with advanced, otherwise untreatable malignancies. Modern medicine often balances potential side effects against life-saving benefits, and strategies to manage treatment-induced anemia are well-established.
Potential Therapeutic Strategies: Targeting EPO Signaling
The research points to several promising therapeutic strategies:
- Direct EPO Blockade: Developing agents that neutralize EPO itself, preventing it from binding to its receptor. This would be a more systemic approach, potentially leading to anemia.
- EPOR Blockade on Macrophages: A more targeted approach would involve selectively blocking the EPO receptors on the surfaces of macrophages within the tumor microenvironment. This could potentially mitigate systemic side effects by focusing the intervention where it is most needed, leaving EPO’s hematopoietic function largely undisturbed elsewhere in the body. Developing such macrophage-specific inhibitors presents a significant pharmacological challenge but offers a highly attractive therapeutic profile.
- Combination with Immunotherapy: Regardless of the specific EPO-targeting agent, the preclinical data strongly supports its combination with existing immune checkpoint inhibitors like anti-PD-1. This synergistic approach promises to be more effective than either strategy alone, particularly for currently immunotherapy-resistant cancers.
The involvement of the pharmaceutical company ImmunEdge Inc. (with Chiu as a cofounder and Engleman as a founder, shareholder, and board member) and the filing of a patent application ("EPO receptor agonists and antagonists") indicate that active steps are already underway to translate this scientific discovery into tangible therapeutic products.
Broader Implications for Cancer Treatment
This research extends far beyond liver cancer, offering a paradigm shift in our understanding of the tumor microenvironment and opening up new avenues for treatment across a wide spectrum of malignancies.
Revolutionizing Immunotherapy for Resistant Cancers
The most significant implication is the potential to revolutionize immunotherapy for cancers currently resistant to treatment. Liver, pancreas, colon, breast, and prostate cancers, which often present as "cold" tumors, represent a massive unmet medical need. By providing a mechanism to "heat up" these tumors, the discovery could make millions of patients candidates for life-saving immunotherapies that were previously ineffective for them. This could significantly expand the reach and efficacy of a therapeutic modality that has already transformed cancer care for some.
The concept of converting an immunosuppressive microenvironment into an immune-permissive one is a holy grail in immuno-oncology. The identification of EPO as a key orchestrator of this process provides a concrete, actionable target to achieve this transformation.
A Paradigm Shift in Understanding Tumor Microenvironments
The study challenges long-held assumptions about the role of seemingly "simple" growth factors in cancer. It demonstrates that the complex interplay within the tumor microenvironment involves many actors, and that molecules with well-defined systemic functions can have entirely different, context-dependent roles within the confined, pathological space of a tumor. The finding highlights the intricate mechanisms by which tumors evade immune surveillance and underscores the importance of studying the entire tumor ecosystem, not just the cancer cells themselves. This paradigm shift will likely stimulate further research into other established growth factors and hormones, prompting oncologists and basic scientists to re-examine their potential roles in immune modulation.
Collaborative Efforts and Funding
The success of this complex research was a testament to collaborative efforts. Researchers from the New York Blood Center and ImmunEdge Inc. contributed to the study, reflecting the interdisciplinary nature of modern biomedical research. Financial support from prestigious institutions like the National Institutes of Health (NIH) through multiple grants (R01CA262361, P01CA244114, U54CA2745115, and P01HL149626) was crucial in enabling the extensive and meticulous experimentation required for such a fundamental discovery.
In conclusion, the unmasking of erythropoietin’s critical role in cancer immune suppression marks a monumental step forward. It not only resolves a long-standing paradox in cancer biology but also offers tangible, innovative strategies to enhance the efficacy of immunotherapies, promising a brighter future for countless cancer patients worldwide. The scientific community eagerly anticipates the swift translation of these findings into clinical practice, driven by the profound optimism articulated by its discoverers.
About the Author
